US20030192532A1 - Nebulizer - Google Patents

Nebulizer Download PDF

Info

Publication number
US20030192532A1
US20030192532A1 US10/121,237 US12123702A US2003192532A1 US 20030192532 A1 US20030192532 A1 US 20030192532A1 US 12123702 A US12123702 A US 12123702A US 2003192532 A1 US2003192532 A1 US 2003192532A1
Authority
US
United States
Prior art keywords
frequency
transducer
nebulizer
current
fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/121,237
Inventor
Andrew Hopkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/121,237 priority Critical patent/US20030192532A1/en
Publication of US20030192532A1 publication Critical patent/US20030192532A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0085Inhalators using ultrasonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00Characteristics of a physical parameter; associated device therefor
    • A61M2206/10Flow characteristics
    • A61M2206/16Rotating swirling helical flow, e.g. by tangential inflows
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00Characteristics of a physical parameter; associated device therefor
    • A61M2206/10Flow characteristics
    • A61M2206/18Coaxial flows, e.g. one flow within another

Definitions

  • the present invention relates to a nebulizer and, particularly, but not exclusively, to an ultrasonic nebulizer suitable for nebulizing/atomizing liquid based medication for the purpose of inhalation by a patient.
  • liquid nebulizers It is well known for liquid nebulizers to employ ultrasonic technology to provide a required degree of liquid atomization.
  • Conventional ultrasonic nebulizers incorporate a piezo-oscillator element (i.e. a piezo-electric crystal) which is exposed to a liquid to be atomized and selectively excited by means of an electric oscillating circuit. Upon excitation, the piezo-oscillator element acts as a transducer and generates ultrasonic waves in the liquid, which are directed to the liquid surface. As a consequence, the surface of said liquid is atomized into a fine mist, which may be transported, as necessary, by suitable means such as an electric fan or simply by the inhalation of a patient.
  • suitable means such as an electric fan or simply by the inhalation of a patient.
  • FIGS. 1 a, 1 b and 1 c Both the electrical and mist generating characteristics of a typical piezo-oscillator element are schematically shown in FIGS. 1 a, 1 b and 1 c of the accompanying drawings. It will be seen by reference to FIG. 1 a that the effective reactance of a piezo-oscillator element is inductive (i.e. positive) at frequencies between a series (resonance) frequency f r and a parallel (anti-resonance) frequency f a of the transducer.
  • the effective reactance of the piezo-oscillator element is capacitive (i.e. negative). Also, it will be seen from FIG. 1 b that the effective impedance of a piezo-oscillator element is minimized at the resonance frequency f r and maximized at the anti-resonance frequency f a .
  • the majority of conventional ultrasonic nebulizers incorporate oscillating circuitry, which uses one of these frequencies as a basis for exciting the piezo-oscillating element.
  • the oscillating circuitry is designed to automatically tune to one of said frequencies so that variations in, for example, ambient conditions, may be conveniently accommodated.
  • a number of methods are employed for achieving this automatic tuning, one of which uses the voltage and current phases in respect of a piezo-oscillating element in conjunction with a phase comparator (see, for example, U.S. Pat. No. 3,819,961).
  • a problem associated with the prior art systems for controlling the oscillation frequency of piezo-oscillating elements is that such systems are generally relatively complicated.
  • a first aspect of the present invention provides a nebulizer comprising an electrically energizable ultrasonic transducer having an oscillation frequency dependent current and voltage characteristic exhibiting the occurrence of a minimum magnitude of current through the transducer at an anti-resonance frequency of the transducer, the voltage across the transducer increasing with an increase in frequency within a range of frequencies including said anti-resonance frequency; a transducer drive system for generating a drive signal for energizing the transducer, the drive system comprising oscillation frequency control means operable to maintain the frequency of the drive signal at a specific frequency within said range of frequencies by reference to the variation of both current through the transducer and voltage across the transducer with a change of frequency within the said frequency range, the transducer being arranged to receive said drive signal and to cause physical vibrations in the fluid to be nebulized when energized by said drive signal.
  • the oscillation frequency control means it is preferable for the oscillation frequency control means to maintain the frequency of the drive signal at a magnitude at which the variation with frequency of a function of current through the transducer is zero. It is also preferable for the function of current to have a zero variation with frequency at a frequency magnitude other than the anti-resonance frequency of the transducer.
  • the function of current may have a zero variation with frequency at a frequency magnitude at which the yield of fluid nebulized by the transducer is substantially maximised.
  • the oscillation frequency control means may comprise a comparator for determining the direction of change with frequency of the function of current through the transducer. Furthermore, the oscillation frequency control means may also comprise a comparator for determining the direction of change with frequency of voltage across the transducer. Preferably, outputs from the two comparators are applied to an exclusive OR gate for determination of the frequency magnitude at which the function of current has a zero variation with frequency. The function of current may be such that the relationship of said function with frequency is identical to that of current through the transducer with frequency.
  • a second aspect of the present invention provides a nebulizer comprising means for inducing a swirling motion in nebulized fluid about a swirl axis as said nebulized fluid is extracted from the nebulizer, the angular velocity of the swirling fluid being sufficient to result in undesirably large nebulized particles moving in a direction offset to the direction of swirl and thereby away from the swirl axis.
  • a nebulizer comprising means for inducing a swirling motion in nebulized fluid about a swirl axis as said nebulized fluid is extracted from the nebulizer, the angular velocity of the swirling fluid being sufficient to result in undesirably large nebulized particles moving in a direction offset to the direction of swirl and thereby away from the swirl axis.
  • oversized nebulized/atomized particles are effectively thrown from the swirling fluid. These oversized particles maybe then collected and returned to a fluid reservoir.
  • the means for inducing a swirling motion in nebulized fluid preferably comprises one or more guides for deflecting a flow of fluid.
  • the guide may be a curved guide or vane.
  • the nebulizer preferably comprises a first chamber, in which fluid is nebulized, and a second chamber having an inlet and outlet and in which the means for inducing a swirling motion is arranged so as to induce a swirling motion in fluid passing through the second chamber from said inlet to said outlet; the first and second chambers being in fluid communication so that, when in use, swirling fluid in the second chamber tends to draw nebulized fluid into said second chamber from the first chamber.
  • the means by which the first and second chambers are in fluid communication preferably comprises a passage joining the first and second chambers wherein said passage is centered on the swirl axis.
  • the passage may comprise an aperture in a wall common to both the first and second chambers.
  • Means may be provided for allowing fluid to flow into the first chamber as nebulized fluid is drawn into the second chamber.
  • the nebulizer preferably comprises means for collecting undesirably large nebulized particles, which have moved away from the swirl axis. Said collection means preferably directs collected particles to the first chamber for re-nebulization.
  • the first chamber preferably comprises a tube located above the surface of liquid to be nebulized so that the interior of the tube receives the majority of any nebulized fluid.
  • One or more slots may be provided in the wall of the tube so as to allow nebulized fluid to pass from the interior of the tube to the exterior thereof.
  • a third aspect of the present invention provides a nebulizer comprising a demand prediction system which determines the period of a cyclical demand for nebulized fluid by monitoring fluid flow with detection means so as to determine the start of consecutive demand cycles and compensating for lag between the actual start of a demand cycle and the detected start of said cycle by calculating the start of a next demand cycle as being a length of time from the detected start of a current demand cycle where said length of time is equal to the determined period less a fixed length of time.
  • Said fixed length of time may be equal to or greater than the length of time between the actual start of a demand cycle and the detected start of said cycle.
  • the detection means preferably comprises a thermistor.
  • FIGS. 1 a, 1 b and 1 c respectively show the variation with frequency of reactance, impedance and quality of mist generation of a piezo-oscillator element
  • FIG. 2 shows a schematic perspective view of a nebulizer according to the present invention
  • FIG. 3 shows a schematic partial perspective view of the nebulizer shown in FIG. 2;
  • FIG. 4 shows graphically the basis for operation of a breath prediction system
  • FIG. 5 shows the variation with frequency of voltage across a transducer (i.e. a piezo-oscillator element) and of current through a transducer;
  • FIG. 6 is a block diagram showing the structure of the electric circuit of the nebulizer shown in FIG. 2;
  • FIG. 7 is a diagram of the control circuitry of the nebulizer shown in FIG. 2;
  • FIG. 8 is a diagram of the power supply circuitry of the nebulizer shown in FIG. 2;
  • FIG. 9 is a block diagram showing the interface between the control circuitry of FIG. 7 and the power supply circuitry of FIG. 8.
  • a nebulizer 10 incorporates a reservoir 12 for retaining a liquid based medication 14 to be nebulized (see FIGS. 2 and 3).
  • This liquid 14 may include a solution or suspension of solid compounds.
  • an ultrasonic transducer 16 i.e. a piezo-oscillator element
  • the transducer 16 is itself connected to appropriate electrical control circuitry (not shown in FIGS. 2 and 3) for providing excitation energy at a required frequency.
  • the control circuitry is powered by means of rechargeable batteries.
  • a nebulizing chamber 18 is located above the surface 20 of the liquid medication 14 so as to receive liquid, which has been atomized.
  • a mouthpiece 22 extends into the nebulizing chamber 18 to allow a user of the nebulizer 10 (i.e. a patient) to inhale any atomized medication produced following excitation of the transducer 16 .
  • the lower end of the mouthpiece 22 is located adjacent the transducer 16 so as to receive all (or a substantial proportion) of the atomized medication generated during excitation.
  • Atomized mediation is generally ejected from the surface of the liquid 14 as a fountain of small particles.
  • a barrier member 21 is located in the mouthpiece 22 .
  • the barrier member 21 is in the form of a concave dome and completely blocks the passage of fluid through the mouthpiece 22 .
  • atomized medication to be inhaled by a patient bypasses the barrier member 21 by flowing from a location in the mouthpiece 22 below said member 21 into the nebulizing chamber 18 via one of four elongate slots 23 .
  • the slots 23 are equi-spaced about the circumference of the mouthpiece 22 .
  • the atomized medication then flows through one of two apertures 25 to a location in the mouthpiece 22 above the barrier member 21 .
  • the two apertures 25 are located on opposite sides of the mouthpiece 22 .
  • An inlet port 24 ensures that fluid pressure within the nebulizer 10 is equalised with the atmospheric pressure external to the nebulizer 10 as atomized medication is inhaled.
  • the nebulizer 10 further incorporates breath actuation means (not shown in FIGS. 2 and 3) in the form of electric circuitry, which ensures that atomized medication is generated only as and when it is required by the user. In this way, the components of the nebulizer 10 are not used unnecessarily and, accordingly, the efficiency of the atomization process is improved and the service life of the nebulizer 10 is extended.
  • the breath actuation means of the present embodiment incorporates a heated thermistor exposed to the flow path of atomized liquid drawn from the nebulizing chamber 18 . As a fluid flow is initiated upon the inhalation of a patient, the heated thermistor is cooled. This produces a change in thermistor resistance. Excitation of the transducer 16 may be thereby triggered.
  • the nebulizer being turned on at the same as the user begins to inhale. It will however be appreciated that in one embodiment the first two breaths of the user allow a calculation of the breath period X and, accordingly, anticipation of the user's inhalations is only made for the user's third and subsequent breaths.
  • the continual monitoring of each breath allows adjustments to be made for variations in the user's rate of breathing. In other words, the system allows for variations in the breath period X.
  • the system maybe configured to initiate excitation of the transducer slightly before the anticipated inhalation of a user so as to pre-fill the nebulizing chamber 18 with atomized medication. This results in a faster treatment time. Furthermore, because of the characteristics of a thermistor as a flow sensor, nebulization maybe terminated before the end of inhalation so as to reduce the amount of medication being re-breathed into the atmosphere.
  • This demand prediction system is preferably implemented by means of appropriate electronic circuitry.
  • the breath actuation means may be designed so that, once initiated, atomization continues until the heated thermistor senses a temperature change indicating the end of patient inhalation.
  • the breath actuation means may be designed so that atomization is terminated when the heated thermistor senses a decrease in breathing rate to, for example, 80% of the maximum breathing rate detected during the current breath.
  • atomization may be terminated after a fixed pre-determined time period or after a period dependent upon the length of the previous breath.
  • Termination of atomization may also be made dependent upon the period of time taken for the thermistor to detect a pre-determined change in the peak value measured during the current breath or the average value of the previous breaths, wherein said pre-determined change is a pre-determined percentage of said peak value.
  • Breath actuation means employing a heated thermistor to detect fluid flow is disclosed in EP 0 178 925 A2.
  • the present embodiment also incorporates means for detecting when the reservoir 12 has been emptied (or is about to be emptied) of the liquid based medication 14 and for switching off the nebulizer 10 upon such detection and indicating to the user that the source of medication has been exhausted (or is about to be exhausted).
  • the means for detecting exhaustion of the medication source incorporates control logic, which compares the current passing through the transducer with pre-determined values of current magnitude corresponding to a minimum acceptable level of liquid medication.
  • the control logic can be conveniently designed to switch off the nebulizer once the magnitude of the transducer current has dropped to the predetermined level.
  • an LED i.e. a Light Emitting Diode
  • Appropriate means for detecting a minimum acceptable level of liquid within the reservoir 12 is disclosed in GB 2,219,512 A.
  • the present embodiment is provided with a transducer capable of generating maximum quantities of mist in a frequency range of approximately 1 to 2.5 MHz. This frequency range produces particles of the desired size.
  • many prior art nebulizers limit particle size by means of a baffle system. However, the effectiveness of such systems is heavily dependent upon fluid flow velocity and the resultant impinging of particles on one or more baffles tends to result in a large proportion of medication (i.e. residual medication) not being inhaled by the patient.
  • the present nebulizer 10 incorporates two vanes 26 , 27 (although a single vane may be sufficient) for generating fluid swirl in an upper portion 28 of the mouthpiece 22 .
  • the two vanes 26 , 27 are located in an upper chamber 30 situated above the nebulizing chamber 18 .
  • a wall 32 common to both the upper chamber 30 and the nebulizing chamber 18 is provided with two apertures 34 , 36 which, in use, permit air to flow into the nebulizing chamber 18 from the upper chamber 30 .
  • a central aperture 38 is also provided in the wall 32 for permitting a flow of air and atomized medication to pass from the nebulizing chamber 18 into the upper chamber 30 via a lower portion 40 of the mouthpiece 22 .
  • a second central aperture 42 is defined opposite said first central aperture 38 in an upper wall 44 (not shown in FIG. 3) of the nebulizer 10 .
  • the upper portion 28 of the mouthpiece 22 extends from the second central aperture 42 outwardly from the upper chamber 30 .
  • the mouthpiece 22 does not extend through the upper chamber 30 .
  • the two vanes 26 , 27 are arranged to generate a swirling flow of fluid in the region between the two central apertures 38 , 42 .
  • the arrangement is such that, in use, inhalation by a patient through the upper portion 28 of the mouthpiece 22 causes air to enter the nebulizer 10 at the inlet port 24 .
  • FIG. 3 it will be seen that the intake of air progresses into the upper chamber 30 where it is separated into two distinct flows by a first vane 26 .
  • the vanes 26 , 27 and a curved sidewall 46 of the upper chamber 30 are such that the separated airflows are directed to the centre of the upper chamber 30 between the two central apertures 38 , 42 .
  • the airflows are so directed that a swirling motion is induced therein.
  • Vortices 48 are formed in the region of the central apertures 38 , 42 which, due to their lower static fluid pressure, tend to draw a mixture of air and atomized medication from the nebulizing chamber 18 into the upper chamber 30 via the lower portion 40 of the mouthpiece 22 .
  • This fluid flow from the nebulizing chamber 18 results in a flow of air into the nebulizing chamber 18 from the upper chamber 30 via the apertures 34 , 36 .
  • the vortices 48 and atomized medication drawn into the upper chamber 30 are inhaled by the patient via the upper portion 28 of the mouthpiece 22 .
  • At least one vane may include a radius of curvature, which decreases in a direction towards the swirl axis.
  • the mouthpiece of an alternative embodiment may be provided as two concentrically mounted tubes wherein atomized medication is inhaled by a patient through the inner tube while pressure equalization within the nebulizer is achieved by virtue of an air flow into the nebulizer which passes through a generally annular shaped passage formed between said tubes.
  • pressure equalization within the nebulizer is achieved by virtue of an air flow into the nebulizer which passes through a generally annular shaped passage formed between said tubes.
  • FIGS. 7 and 8 The control and power supply circuits of the present embodiment are illustratively shown in FIGS. 7 and 8 respectively. The relationship between these two circuits is illustratively shown in FIG. 9.
  • the general structure of the nebulizer circuitry is illustratively shown in FIG. 6.
  • An automatic tuning circuit (see FIG. 7) is comprised in the control circuitry for automatically tuning transducer oscillation to a specific frequency. This tuning circuit operates on the basis of the transducer current/voltage and frequency relationship shown in FIG. 5.
  • the aforementioned transducer characteristic may be conveniently used to automatically tune to the anti-resonance frequency.
  • the tuning circuit comprises two comparators for determining the direction of change (i.e. increase or decrease) of either transducer voltage or current with frequency.
  • One of the comparators is presented with a voltage representing the magnitude of the current through the transducer, while the other comparator is presented with a voltage representing the magnitude of the voltage across the transducer.
  • a part of the signal applied to each comparator is delayed for comparison with the instant signal. It may then be determined whether or not the applied signal is momentarily rising or falling.
  • the output of the two comparators is applied to an exclusive OR gate in order to determine whether the transducer frequency is greater than or less than the frequency at which the transducer current is a minimum (i.e. the anti-resonance frequency f a ). On the basis of this determination, the frequency may be appropriately adjusted.
  • the exclusive OR gate produces a clock output of varying pulse widths which is averaged with an integrator (see FIG. 7) so as to produce a signal for driving a voltage controlled oscillator.
  • This oscillator is operable at frequencies of approximately 2.5 MHz so as to ensure that, as previously discussed, the atomized liquid is generated with the desired particle size.
  • the output drive circuit comprises two field-effect transistors (i.e. two FETs) arranged in a totem-pole configuration so as to allow the piezo-electric transducer of the nebulizer to be referenced to ground.
  • a level-shifting network comprising a small transformer is provided in the output drive circuit for stepping up the circuit voltage to between 40V and 100V. This higher voltage is used to drive the upper FET.
  • the illustrated output drive circuit and automatic tuning circuit generate a measured rectified and smoothed transducer voltage/current and tune the oscillator to the required anti-resonance frequency.
  • the circuitry of the nebulizer may be configured so as to automatically tune to a frequency, which is offset from the anti-resonance frequency f a . This is achieved by manipulating the transducer voltage and current magnitudes so as to generate a frequency curve having a maximum or minimum occurring at a frequency other than that at which the minimum current through the transducer is found. This new maximum or minimum is then used as a new reference for the automatic tuning.
  • the tuning frequency can be offset by reference to the modulus of resistance (i.e. V/I) of the transducer. This is found by dividing the measured rectified and smoothed voltage across the transducer by the measured rectified and smoothed current through the transducer.
  • a curve is thereby produced which has a maximum occurring at a frequency greater than the frequency at which the minimum current occurs (i.e. the anti-resonance frequency f a ).
  • the V/I function is derived in practice by a divider circuit.
  • these voltage and current variables may be either added (V+I), subtracted (V ⁇ I) or multiplied (V ⁇ I) so as to generate an offsetting of frequency from the anti-resonance frequency.

Abstract

The present invention relates to a nebulizer comprising an electrically energizable ultrasonic transducer having an oscillation frequency dependent current and voltage characteristic exhibiting the occurrence of a minimum magnitude of current through the transducer at an anti-resonance frequency of the transducer, the voltage across the transducer increasing with an increase in frequency within a range of frequencies including said anti-resonance frequency. The nebulizer further comprises a transducer drive system for generating a drive signal for energising the transducer, the drive system comprising oscillation frequency control means operable to maintain the frequency of the drive signal at a specific frequency within said range of frequencies by reference to the variation of both current through the transducer and voltage across the transducer with a change of frequency within the said frequency range. The transducer is arranged to receive said drive signal and to cause physical vibrations in fluid to be nebulized when energised by said drive signal. A transducer having a simple automatic frequency tuning system is thereby provided.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a nebulizer and, particularly, but not exclusively, to an ultrasonic nebulizer suitable for nebulizing/atomizing liquid based medication for the purpose of inhalation by a patient. [0001]
  • BACKGROUND OF THE INVENTION
  • It is well known for liquid nebulizers to employ ultrasonic technology to provide a required degree of liquid atomization. Conventional ultrasonic nebulizers incorporate a piezo-oscillator element (i.e. a piezo-electric crystal) which is exposed to a liquid to be atomized and selectively excited by means of an electric oscillating circuit. Upon excitation, the piezo-oscillator element acts as a transducer and generates ultrasonic waves in the liquid, which are directed to the liquid surface. As a consequence, the surface of said liquid is atomized into a fine mist, which may be transported, as necessary, by suitable means such as an electric fan or simply by the inhalation of a patient. [0002]
  • The characteristics of piezo-oscillator elements are well known and must be carefully considered when designing the oscillating circuit of a nebulizer if efficient liquid atomization is to be achieved. Both the electrical and mist generating characteristics of a typical piezo-oscillator element are schematically shown in FIGS. 1[0003] a, 1 b and 1 c of the accompanying drawings. It will be seen by reference to FIG. 1a that the effective reactance of a piezo-oscillator element is inductive (i.e. positive) at frequencies between a series (resonance) frequency fr and a parallel (anti-resonance) frequency fa of the transducer. At other frequencies, the effective reactance of the piezo-oscillator element is capacitive (i.e. negative). Also, it will be seen from FIG. 1b that the effective impedance of a piezo-oscillator element is minimized at the resonance frequency fr and maximized at the anti-resonance frequency fa.
  • The oscillation amplitude of a piezo-oscillator element is maximized at the resonance frequency f[0004] r, however it will be seen from FIG. 1c that this frequency fr is somewhat less than the optimum frequency fom for maximizing liquid atomization. Indeed, the optimum frequency fom for maximum yield of mist is between the resonance frequency fr and the anti-resonance frequency fa.
  • Notwithstanding the fact that the optimum frequency in terms of mist generation is between the resonance and anti-resonance frequencies, the majority of conventional ultrasonic nebulizers incorporate oscillating circuitry, which uses one of these frequencies as a basis for exciting the piezo-oscillating element. Typically, the oscillating circuitry is designed to automatically tune to one of said frequencies so that variations in, for example, ambient conditions, may be conveniently accommodated. A number of methods are employed for achieving this automatic tuning, one of which uses the voltage and current phases in respect of a piezo-oscillating element in conjunction with a phase comparator (see, for example, U.S. Pat. No. 3,819,961). However, a problem associated with the prior art systems for controlling the oscillation frequency of piezo-oscillating elements is that such systems are generally relatively complicated. [0005]
  • In order for a medication dispensed by a nebulizer to be adequately received by a patient, it is important for the atomized liquid particles to have an appropriate size. Release of undesirably large particles is prevented in many prior art nebulizers by means of a baffle system. However, the effectiveness of such systems is heavily dependent upon fluid flow velocity and the resultant impinging of particles on one or more baffles tends to leave a large proportion of medication, which is not inhaled. This reduces the overall effectiveness and efficiency of prior art nebulizers. [0006]
  • SUMMARY
  • It is an object of the present invention to provide an ultrasonic nebulizer comprising means for automatically tuning to a required oscillation frequency wherein said means is comparatively simple and may be readily and inexpensively manufactured. [0007]
  • It is also an object of the present invention to provide a nebulizer incorporating effective and efficient means for controlling the size of atomized particles. [0008]
  • A first aspect of the present invention provides a nebulizer comprising an electrically energizable ultrasonic transducer having an oscillation frequency dependent current and voltage characteristic exhibiting the occurrence of a minimum magnitude of current through the transducer at an anti-resonance frequency of the transducer, the voltage across the transducer increasing with an increase in frequency within a range of frequencies including said anti-resonance frequency; a transducer drive system for generating a drive signal for energizing the transducer, the drive system comprising oscillation frequency control means operable to maintain the frequency of the drive signal at a specific frequency within said range of frequencies by reference to the variation of both current through the transducer and voltage across the transducer with a change of frequency within the said frequency range, the transducer being arranged to receive said drive signal and to cause physical vibrations in the fluid to be nebulized when energized by said drive signal. [0009]
  • It is preferable for the oscillation frequency control means to maintain the frequency of the drive signal at a magnitude at which the variation with frequency of a function of current through the transducer is zero. It is also preferable for the function of current to have a zero variation with frequency at a frequency magnitude other than the anti-resonance frequency of the transducer. The function of current may have a zero variation with frequency at a frequency magnitude at which the yield of fluid nebulized by the transducer is substantially maximised. [0010]
  • The oscillation frequency control means may comprise a comparator for determining the direction of change with frequency of the function of current through the transducer. Furthermore, the oscillation frequency control means may also comprise a comparator for determining the direction of change with frequency of voltage across the transducer. Preferably, outputs from the two comparators are applied to an exclusive OR gate for determination of the frequency magnitude at which the function of current has a zero variation with frequency. The function of current may be such that the relationship of said function with frequency is identical to that of current through the transducer with frequency. [0011]
  • A second aspect of the present invention provides a nebulizer comprising means for inducing a swirling motion in nebulized fluid about a swirl axis as said nebulized fluid is extracted from the nebulizer, the angular velocity of the swirling fluid being sufficient to result in undesirably large nebulized particles moving in a direction offset to the direction of swirl and thereby away from the swirl axis. Thus, oversized nebulized/atomized particles are effectively thrown from the swirling fluid. These oversized particles maybe then collected and returned to a fluid reservoir. [0012]
  • The means for inducing a swirling motion in nebulized fluid preferably comprises one or more guides for deflecting a flow of fluid. The guide may be a curved guide or vane. [0013]
  • The nebulizer preferably comprises a first chamber, in which fluid is nebulized, and a second chamber having an inlet and outlet and in which the means for inducing a swirling motion is arranged so as to induce a swirling motion in fluid passing through the second chamber from said inlet to said outlet; the first and second chambers being in fluid communication so that, when in use, swirling fluid in the second chamber tends to draw nebulized fluid into said second chamber from the first chamber. The means by which the first and second chambers are in fluid communication preferably comprises a passage joining the first and second chambers wherein said passage is centered on the swirl axis. The passage may comprise an aperture in a wall common to both the first and second chambers. Means may be provided for allowing fluid to flow into the first chamber as nebulized fluid is drawn into the second chamber. [0014]
  • The nebulizer preferably comprises means for collecting undesirably large nebulized particles, which have moved away from the swirl axis. Said collection means preferably directs collected particles to the first chamber for re-nebulization. [0015]
  • The first chamber preferably comprises a tube located above the surface of liquid to be nebulized so that the interior of the tube receives the majority of any nebulized fluid. One or more slots may be provided in the wall of the tube so as to allow nebulized fluid to pass from the interior of the tube to the exterior thereof. [0016]
  • A third aspect of the present invention provides a nebulizer comprising a demand prediction system which determines the period of a cyclical demand for nebulized fluid by monitoring fluid flow with detection means so as to determine the start of consecutive demand cycles and compensating for lag between the actual start of a demand cycle and the detected start of said cycle by calculating the start of a next demand cycle as being a length of time from the detected start of a current demand cycle where said length of time is equal to the determined period less a fixed length of time. [0017]
  • Said fixed length of time may be equal to or greater than the length of time between the actual start of a demand cycle and the detected start of said cycle. The detection means preferably comprises a thermistor.[0018]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • An embodiment of the present invention will now be described with reference to the accompanying drawings, in which: [0019]
  • FIGS. 1[0020] a, 1 b and 1 c respectively show the variation with frequency of reactance, impedance and quality of mist generation of a piezo-oscillator element;
  • FIG. 2 shows a schematic perspective view of a nebulizer according to the present invention; [0021]
  • FIG. 3 shows a schematic partial perspective view of the nebulizer shown in FIG. 2; [0022]
  • FIG. 4 shows graphically the basis for operation of a breath prediction system; [0023]
  • FIG. 5 shows the variation with frequency of voltage across a transducer (i.e. a piezo-oscillator element) and of current through a transducer; [0024]
  • FIG. 6 is a block diagram showing the structure of the electric circuit of the nebulizer shown in FIG. 2; [0025]
  • FIG. 7 is a diagram of the control circuitry of the nebulizer shown in FIG. 2; [0026]
  • FIG. 8 is a diagram of the power supply circuitry of the nebulizer shown in FIG. 2; and [0027]
  • FIG. 9 is a block diagram showing the interface between the control circuitry of FIG. 7 and the power supply circuitry of FIG. 8. [0028]
  • DETAILED DESCRIPTION OF THE INVENTION
  • A [0029] nebulizer 10 according to the present invention incorporates a reservoir 12 for retaining a liquid based medication 14 to be nebulized (see FIGS. 2 and 3). This liquid 14 may include a solution or suspension of solid compounds. As is known in the art, an ultrasonic transducer 16 (i.e. a piezo-oscillator element) is mounted relative to the reservoir 12 so as to be exposed to the liquid medication 14. The transducer 16 is itself connected to appropriate electrical control circuitry (not shown in FIGS. 2 and 3) for providing excitation energy at a required frequency. The control circuitry is powered by means of rechargeable batteries.
  • A [0030] nebulizing chamber 18 is located above the surface 20 of the liquid medication 14 so as to receive liquid, which has been atomized. A mouthpiece 22 extends into the nebulizing chamber 18 to allow a user of the nebulizer 10 (i.e. a patient) to inhale any atomized medication produced following excitation of the transducer 16. The lower end of the mouthpiece 22 is located adjacent the transducer 16 so as to receive all (or a substantial proportion) of the atomized medication generated during excitation. Atomized mediation is generally ejected from the surface of the liquid 14 as a fountain of small particles. In order to prevent these particles from being undesirably ejected from the nebulizer 10 through the mouthpiece 22, a barrier member 21 is located in the mouthpiece 22. The barrier member 21 is in the form of a concave dome and completely blocks the passage of fluid through the mouthpiece 22. In use, atomized medication to be inhaled by a patient bypasses the barrier member 21 by flowing from a location in the mouthpiece 22 below said member 21 into the nebulizing chamber 18 via one of four elongate slots 23. The slots 23 are equi-spaced about the circumference of the mouthpiece 22. The atomized medication then flows through one of two apertures 25 to a location in the mouthpiece 22 above the barrier member 21. The two apertures 25 are located on opposite sides of the mouthpiece 22.
  • An inlet port [0031] 24 (provided as necessary with an appropriate one way valve) ensures that fluid pressure within the nebulizer 10 is equalised with the atmospheric pressure external to the nebulizer 10 as atomized medication is inhaled.
  • The [0032] nebulizer 10 further incorporates breath actuation means (not shown in FIGS. 2 and 3) in the form of electric circuitry, which ensures that atomized medication is generated only as and when it is required by the user. In this way, the components of the nebulizer 10 are not used unnecessarily and, accordingly, the efficiency of the atomization process is improved and the service life of the nebulizer 10 is extended. The breath actuation means of the present embodiment incorporates a heated thermistor exposed to the flow path of atomized liquid drawn from the nebulizing chamber 18. As a fluid flow is initiated upon the inhalation of a patient, the heated thermistor is cooled. This produces a change in thermistor resistance. Excitation of the transducer 16 may be thereby triggered.
  • Due to the thermal lag of a thermistor, there is a small delay between the start of inhalation and the detection of a breath. Also, once a transducer is excited, there is a small delay before atomized medication is generated. Accordingly, it is preferable for the breath actuation means of the [0033] nebulizer 10 to be turned on for a fixed pre-determined period before actual detection of a breath. With reference to FIG. 4, it will be seen that this is achieved by measuring the period X of a user's previous breathing cycle and using this measured time, less the fixed pre-determined delay time Y, to turn on the nebulizer after a calculated period Z (wherein Z=X−Y) from the detected start of the present breath. This is repeated continually for each breath and, for a series of breaths having the same period, results in the nebulizer being turned on at the same as the user begins to inhale. It will however be appreciated that in one embodiment the first two breaths of the user allow a calculation of the breath period X and, accordingly, anticipation of the user's inhalations is only made for the user's third and subsequent breaths. The continual monitoring of each breath allows adjustments to be made for variations in the user's rate of breathing. In other words, the system allows for variations in the breath period X. Also, by increasing the pre-determined delay time Y, the system maybe configured to initiate excitation of the transducer slightly before the anticipated inhalation of a user so as to pre-fill the nebulizing chamber 18 with atomized medication. This results in a faster treatment time. Furthermore, because of the characteristics of a thermistor as a flow sensor, nebulization maybe terminated before the end of inhalation so as to reduce the amount of medication being re-breathed into the atmosphere. This demand prediction system is preferably implemented by means of appropriate electronic circuitry.
  • The breath actuation means may be designed so that, once initiated, atomization continues until the heated thermistor senses a temperature change indicating the end of patient inhalation. Alternatively, the breath actuation means may be designed so that atomization is terminated when the heated thermistor senses a decrease in breathing rate to, for example, 80% of the maximum breathing rate detected during the current breath. In yet further designs of breath actuation means, atomization may be terminated after a fixed pre-determined time period or after a period dependent upon the length of the previous breath. Termination of atomization may also be made dependent upon the period of time taken for the thermistor to detect a pre-determined change in the peak value measured during the current breath or the average value of the previous breaths, wherein said pre-determined change is a pre-determined percentage of said peak value. Breath actuation means employing a heated thermistor to detect fluid flow is disclosed in [0034] EP 0 178 925 A2.
  • The present embodiment also incorporates means for detecting when the [0035] reservoir 12 has been emptied (or is about to be emptied) of the liquid based medication 14 and for switching off the nebulizer 10 upon such detection and indicating to the user that the source of medication has been exhausted (or is about to be exhausted). The means for detecting exhaustion of the medication source incorporates control logic, which compares the current passing through the transducer with pre-determined values of current magnitude corresponding to a minimum acceptable level of liquid medication.
  • As the [0036] reservoir 12 is emptied, the transducer 16 becomes unloaded and the current passing therethrough reduces. Accordingly, the control logic can be conveniently designed to switch off the nebulizer once the magnitude of the transducer current has dropped to the predetermined level. At this stage, an LED (i.e. a Light Emitting Diode) or similar device may be activated by said control logic so as to provide the required indication to the user. Appropriate means for detecting a minimum acceptable level of liquid within the reservoir 12 is disclosed in GB 2,219,512 A.
  • In order for the medication dispensed by the [0037] nebulizer 10 to be adequately received by a patient, it is important that the particles of the atomized liquid have an appropriate size. Ideally, the diameter of the particles should be between 0.5 :m and 5.0 :m. Accordingly, as in many prior art nebulizer designs, the present embodiment is provided with a transducer capable of generating maximum quantities of mist in a frequency range of approximately 1 to 2.5 MHz. This frequency range produces particles of the desired size. In addition, many prior art nebulizers limit particle size by means of a baffle system. However, the effectiveness of such systems is heavily dependent upon fluid flow velocity and the resultant impinging of particles on one or more baffles tends to result in a large proportion of medication (i.e. residual medication) not being inhaled by the patient.
  • In order to overcome this problem, the [0038] present nebulizer 10 incorporates two vanes 26,27 (although a single vane may be sufficient) for generating fluid swirl in an upper portion 28 of the mouthpiece 22. The two vanes 26,27 are located in an upper chamber 30 situated above the nebulizing chamber 18. A wall 32 common to both the upper chamber 30 and the nebulizing chamber 18 is provided with two apertures 34,36 which, in use, permit air to flow into the nebulizing chamber 18 from the upper chamber 30.
  • A [0039] central aperture 38 is also provided in the wall 32 for permitting a flow of air and atomized medication to pass from the nebulizing chamber 18 into the upper chamber 30 via a lower portion 40 of the mouthpiece 22. A second central aperture 42 is defined opposite said first central aperture 38 in an upper wall 44 (not shown in FIG. 3) of the nebulizer 10. The upper portion 28 of the mouthpiece 22 extends from the second central aperture 42 outwardly from the upper chamber 30. The mouthpiece 22 does not extend through the upper chamber 30. Furthermore, the two vanes 26,27 are arranged to generate a swirling flow of fluid in the region between the two central apertures 38,42.
  • The arrangement is such that, in use, inhalation by a patient through the [0040] upper portion 28 of the mouthpiece 22 causes air to enter the nebulizer 10 at the inlet port 24. By reference to FIG. 3, it will be seen that the intake of air progresses into the upper chamber 30 where it is separated into two distinct flows by a first vane 26. The vanes 26,27 and a curved sidewall 46 of the upper chamber 30 are such that the separated airflows are directed to the centre of the upper chamber 30 between the two central apertures 38,42. The airflows are so directed that a swirling motion is induced therein.
  • [0041] Vortices 48 are formed in the region of the central apertures 38,42 which, due to their lower static fluid pressure, tend to draw a mixture of air and atomized medication from the nebulizing chamber 18 into the upper chamber 30 via the lower portion 40 of the mouthpiece 22. This fluid flow from the nebulizing chamber 18 results in a flow of air into the nebulizing chamber 18 from the upper chamber 30 via the apertures 34,36. The vortices 48 and atomized medication drawn into the upper chamber 30 are inhaled by the patient via the upper portion 28 of the mouthpiece 22.
  • The spinning fluid flow rotates with sufficient velocity for undesirably large particles of atomized medication to be effectively thrown against the [0042] vanes 26,27 (and/or to the sides of the mouthpiece 22). Said large particles of medication are then received in a skirt or gutter (not shown) and thereby directed back to the reservoir 12 under the action of gravity. In this way, the amount of residual medication arising through use of the nebulizer 10 is minimized. In one embodiment, at least one vane may include a radius of curvature, which decreases in a direction towards the swirl axis.
  • With regard to the control of residual medication, the mouthpiece of an alternative embodiment may be provided as two concentrically mounted tubes wherein atomized medication is inhaled by a patient through the inner tube while pressure equalization within the nebulizer is achieved by virtue of an air flow into the nebulizer which passes through a generally annular shaped passage formed between said tubes. Thus, large particles leaving the nebulizer chamber tend to become entrained in the incoming airflow. This further obviates the need for an internal baffle system. [0043]
  • The control and power supply circuits of the present embodiment are illustratively shown in FIGS. 7 and 8 respectively. The relationship between these two circuits is illustratively shown in FIG. 9. The general structure of the nebulizer circuitry is illustratively shown in FIG. 6. An automatic tuning circuit (see FIG. 7) is comprised in the control circuitry for automatically tuning transducer oscillation to a specific frequency. This tuning circuit operates on the basis of the transducer current/voltage and frequency relationship shown in FIG. 5. [0044]
  • With reference to FIG. 5, it will be seen that the current passing through a transducer varies with frequency and falls to a minimum at the parallel (i.e. anti-resonance) frequency f[0045] a of the transducer. In addition, it will be seen that the voltage across the transducer at frequencies in the region of the parallel frequency fa increases with frequency. This current/voltage and frequency relationship is characteristic of ultrasonic transducers and is used in the present nebulizer to provide directional control to the automatic tuning circuit.
  • The aforementioned transducer characteristic may be conveniently used to automatically tune to the anti-resonance frequency. The tuning circuit comprises two comparators for determining the direction of change (i.e. increase or decrease) of either transducer voltage or current with frequency. One of the comparators is presented with a voltage representing the magnitude of the current through the transducer, while the other comparator is presented with a voltage representing the magnitude of the voltage across the transducer. As will be apparent to those skilled in the art, a part of the signal applied to each comparator is delayed for comparison with the instant signal. It may then be determined whether or not the applied signal is momentarily rising or falling. It will be seen that the output of the two comparators is applied to an exclusive OR gate in order to determine whether the transducer frequency is greater than or less than the frequency at which the transducer current is a minimum (i.e. the anti-resonance frequency f[0046] a). On the basis of this determination, the frequency may be appropriately adjusted.
  • The exclusive OR gate produces a clock output of varying pulse widths which is averaged with an integrator (see FIG. 7) so as to produce a signal for driving a voltage controlled oscillator. This oscillator is operable at frequencies of approximately 2.5 MHz so as to ensure that, as previously discussed, the atomized liquid is generated with the desired particle size. It should be understood that the magnitudes and placement of circuit components are shown for illustrative purposes and should not be construed as limiting the present invention. The magnitudes and components may be adjusted and changed by one skilled in the art in view of the present disclosure. [0047]
  • Two anti-phase clocks are used to operate an output drive circuit (see FIG. 7). It will be seen that the output drive circuit comprises two field-effect transistors (i.e. two FETs) arranged in a totem-pole configuration so as to allow the piezo-electric transducer of the nebulizer to be referenced to ground. A level-shifting network comprising a small transformer is provided in the output drive circuit for stepping up the circuit voltage to between 40V and 100V. This higher voltage is used to drive the upper FET. With appropriate signal rectification, the illustrated output drive circuit and automatic tuning circuit generate a measured rectified and smoothed transducer voltage/current and tune the oscillator to the required anti-resonance frequency. [0048]
  • In alternative embodiments, the circuitry of the nebulizer may be configured so as to automatically tune to a frequency, which is offset from the anti-resonance frequency f[0049] a. This is achieved by manipulating the transducer voltage and current magnitudes so as to generate a frequency curve having a maximum or minimum occurring at a frequency other than that at which the minimum current through the transducer is found. This new maximum or minimum is then used as a new reference for the automatic tuning. For example, the tuning frequency can be offset by reference to the modulus of resistance (i.e. V/I) of the transducer. This is found by dividing the measured rectified and smoothed voltage across the transducer by the measured rectified and smoothed current through the transducer. A curve is thereby produced which has a maximum occurring at a frequency greater than the frequency at which the minimum current occurs (i.e. the anti-resonance frequency fa). The V/I function is derived in practice by a divider circuit. As an alternative to dividing the transducer voltage by the transducer current, these voltage and current variables may be either added (V+I), subtracted (V−I) or multiplied (V×I) so as to generate an offsetting of frequency from the anti-resonance frequency.
  • The present invention is not limited to the specific embodiments or methods described above. Alternative arrangements may be apparent to a reader skilled in the art. [0050]

Claims (14)

1. A nebulizer comprising:
an electrically energizable ultrasonic transducer having an oscillation frequency dependent current and voltage characteristic exhibiting the occurrence of a minimum magnitude of current through the transducer at an anti-resonance frequency of the transducer, the voltage across the transducer increasing with an increase in frequency within a range of frequencies including said anti-resonance frequency;
a transducer drive system for generating a drive signal for energizing the transducer, the drive system comprising oscillation frequency control means operable to maintain the frequency of the drive signal at a specific frequency within said range of frequencies by reference to the variation of both current through the transducer and voltage across the transducer with a change of frequency within the said frequency range, the transducer being arranged to receive said drive signal and to cause physical vibrations in fluid to be nebulized when energized by said drive signal.
2. A nebulizer as claimed in claim 1, wherein the oscillation frequency control means maintains the frequency of the drive signal at a magnitude at which the variation with frequency of a function of current through the transducer is zero.
3. A nebulizer as claimed in claim 2, wherein the function of current is such that the relationship of said function with frequency is identical to that of current through the transducer with frequency.
4. A nebulizer as claimed in claim 2, wherein the function of current has a zero variation with frequency at a frequency magnitude other than the anti-resonance frequency of the transducer.
5. A nebulizer as claimed in claim 4, wherein the function of current has a zero variation with frequency at a frequency magnitude at which the yield of fluid nebulized by the transducer is substantially maximized.
6. A nebulizer as claimed in claim 1, wherein the oscillation frequency control means comprises a comparator for determining the direction of change with frequency of the function of current through the transducer.
7. A nebulizer as claimed in claim 6, wherein the oscillation frequency control means comprises a comparator for determining the direction of change with frequency of voltage across the transducer.
8. A nebulizer as claimed in claim 7, wherein outputs from the two comparators are applied to an exclusive OR gate for determination of the frequency magnitude at which the function of current has a zero variation with frequency.
9. A nebulizer comprising means for inducing a swirling motion in nebulized fluid about a swirl axis as said nebulized fluid is extracted from the nebulizer, the angular velocity of the swirling fluid being sufficient to result in undesirably large nebulized particles moving in a direction offset to the direction of swirl and thereby away from the swirl axis.
10. A nebulizer as claimed in claim 9, wherein the means for inducing includes at least one vane.
11. A nebulizer as claimed in claim 9, wherein the at least one vane includes a radius of curvature which decreases in a direction towards the swirl axis.
12. A nebulizer comprising a demand prediction system which determines a period of a cyclical demand for nebulized fluid by monitoring fluid flow with detection means so as to determine the start of consecutive demand cycles and compensating for lag between the actual start of a demand cycle and the detected start of said cycle by calculating the start of a next demand cycle as being a length of time from the detected start of a current demand cycle where said length of time is equal to the determined period less a fixed length of time.
13. A nebulizer as claimed in claim 12, wherein the system includes means for determining when demand has ceased.
14. A nebulizer as claimed in claim 13, wherein the means for determining includes a calculation based on breathing rate.
US10/121,237 2002-04-12 2002-04-12 Nebulizer Abandoned US20030192532A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/121,237 US20030192532A1 (en) 2002-04-12 2002-04-12 Nebulizer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/121,237 US20030192532A1 (en) 2002-04-12 2002-04-12 Nebulizer

Publications (1)

Publication Number Publication Date
US20030192532A1 true US20030192532A1 (en) 2003-10-16

Family

ID=28790277

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/121,237 Abandoned US20030192532A1 (en) 2002-04-12 2002-04-12 Nebulizer

Country Status (1)

Country Link
US (1) US20030192532A1 (en)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140761A1 (en) * 2006-06-07 2007-12-13 Joachim Kern Dosage inhaler
WO2008035033A1 (en) * 2006-09-21 2008-03-27 Dyson Technology Limited A circuit
WO2008061408A1 (en) * 2006-11-22 2008-05-29 Huiliang Liu Flameless medical electronic atomizer
US7883031B2 (en) 2003-05-20 2011-02-08 James F. Collins, Jr. Ophthalmic drug delivery system
US8012136B2 (en) 2003-05-20 2011-09-06 Optimyst Systems, Inc. Ophthalmic fluid delivery device and method of operation
US8607787B2 (en) * 2007-07-06 2013-12-17 Manta Devices, Llc Dose delivery device for inhalation
US8684980B2 (en) 2010-07-15 2014-04-01 Corinthian Ophthalmic, Inc. Drop generating device
US8733935B2 (en) 2010-07-15 2014-05-27 Corinthian Ophthalmic, Inc. Method and system for performing remote treatment and monitoring
US9087145B2 (en) 2010-07-15 2015-07-21 Eyenovia, Inc. Ophthalmic drug delivery
DE102014118578A1 (en) 2014-01-17 2015-07-23 Health & Life Co., Ltd. METHOD AND SPILL MODULE FOR A CONSTANT ELECTRICAL PERFORMANCE THROUGH AUTOMATIC COMPENSATION
CN104826201A (en) * 2015-04-03 2015-08-12 齐俊民 Pediatric medical emergency atomizer
CN105288802A (en) * 2015-10-30 2016-02-03 李道恒 Ultrasonic atomization inhaler
US20160058958A1 (en) * 2009-07-17 2016-03-03 Nektar Therapeutics Systems and methods for driving sealed nebulizers
US9339507B2 (en) 2006-05-15 2016-05-17 United Therapeutics Corporation Treprostinil administration by inhalation
WO2017013072A1 (en) * 2015-07-22 2017-01-26 Linde Aktiengesellschaft A nebuliser
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
WO2019140788A1 (en) * 2018-01-18 2019-07-25 华健 Surge portable micro-network atomizer
US10632268B2 (en) 2005-07-20 2020-04-28 Manta Devices, Llc Inhalation device
US10639194B2 (en) 2011-12-12 2020-05-05 Eyenovia, Inc. High modulus polymeric ejector mechanism, ejector device, and methods of use
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
US20200324225A1 (en) * 2017-05-04 2020-10-15 Flodesign Sonics, Inc. Acoustic transducer controller configuration
US11147936B2 (en) 2014-05-02 2021-10-19 Manta Devices, Llc Dose delivery device with cover connected to dose chamber seal
US20210330621A1 (en) 2020-04-17 2021-10-28 United Therapeutics Corporation Treatment for interstitial lung disease
US11224704B2 (en) 2007-07-06 2022-01-18 Manta Devices, Llc Dose delivery device for inhalation
EP3837999B1 (en) * 2019-12-15 2022-07-27 Shaheen Innovations Holding Limited Mist inhaler devices
US11571022B2 (en) 2019-12-15 2023-02-07 Shaheen Innovations Holding Limited Nicotine delivery device
US11583640B2 (en) 2018-04-20 2023-02-21 Gough Industries, Inc. Medicine vaporizer apparatus and methods of using the same
US11660406B2 (en) 2019-12-15 2023-05-30 Shaheen Innovations Holding Limited Mist inhaler devices
US11665483B1 (en) 2021-12-15 2023-05-30 Shaheen Innovations Holding Limited Apparatus for transmitting ultrasonic waves
US11700882B2 (en) 2019-12-15 2023-07-18 Shaheen Innovations Holding Limited Hookah device
US11730191B2 (en) 2019-12-15 2023-08-22 Shaheen Innovations Holding Limited Hookah device
US11911559B2 (en) 2019-12-15 2024-02-27 Shaheen Innovations Holding Limited Ultrasonic mist inhaler
US11938056B2 (en) 2017-06-10 2024-03-26 Eyenovia, Inc. Methods and devices for handling a fluid and delivering the fluid to the eye
US11944120B2 (en) 2019-12-15 2024-04-02 Shaheen Innovations Holding Limited Ultrasonic mist inhaler with capillary retainer
US11944121B2 (en) 2019-12-15 2024-04-02 Shaheen Innovations Holding Limited Ultrasonic mist inhaler with capillary element

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819961A (en) * 1972-01-03 1974-06-25 Philips Corp Arrangement for generating ultrasonic oscillations
US3989042A (en) * 1974-06-06 1976-11-02 Tdk Electronics Company, Limited Oscillator-exciting system for ultrasonic liquid nebulizer
US5113116A (en) * 1989-10-05 1992-05-12 Firma J. Eberspacher Circuit arrangement for accurately and effectively driving an ultrasonic transducer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819961A (en) * 1972-01-03 1974-06-25 Philips Corp Arrangement for generating ultrasonic oscillations
US3989042A (en) * 1974-06-06 1976-11-02 Tdk Electronics Company, Limited Oscillator-exciting system for ultrasonic liquid nebulizer
US5113116A (en) * 1989-10-05 1992-05-12 Firma J. Eberspacher Circuit arrangement for accurately and effectively driving an ultrasonic transducer

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883031B2 (en) 2003-05-20 2011-02-08 James F. Collins, Jr. Ophthalmic drug delivery system
US8012136B2 (en) 2003-05-20 2011-09-06 Optimyst Systems, Inc. Ophthalmic fluid delivery device and method of operation
US8545463B2 (en) 2003-05-20 2013-10-01 Optimyst Systems Inc. Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
US8936021B2 (en) 2003-05-20 2015-01-20 Optimyst Systems, Inc. Ophthalmic fluid delivery system
US10632268B2 (en) 2005-07-20 2020-04-28 Manta Devices, Llc Inhalation device
US11672927B2 (en) 2005-07-20 2023-06-13 Manta Devices, Llc Inhalation device
US11491287B2 (en) 2005-07-20 2022-11-08 Manta Devices, Llc Inhalation device
US10376525B2 (en) 2006-05-15 2019-08-13 United Therapeutics Corporation Treprostinil administration by inhalation
US10716793B2 (en) 2006-05-15 2020-07-21 United Therapeutics Corporation Treprostinil administration by inhalation
US9358240B2 (en) 2006-05-15 2016-06-07 United Therapeutics Corporation Treprostinil administration by inhalation
US9339507B2 (en) 2006-05-15 2016-05-17 United Therapeutics Corporation Treprostinil administration by inhalation
US11357782B2 (en) 2006-05-15 2022-06-14 United Therapeutics Corporation Treprostinil administration by inhalation
US9155846B2 (en) 2006-06-07 2015-10-13 United Therapeutics Corporation Dosage inhaler
US10806869B2 (en) 2006-06-07 2020-10-20 United Therapeutics Corporation Dosage inhaler
WO2007140761A1 (en) * 2006-06-07 2007-12-13 Joachim Kern Dosage inhaler
WO2008035033A1 (en) * 2006-09-21 2008-03-27 Dyson Technology Limited A circuit
WO2008061408A1 (en) * 2006-11-22 2008-05-29 Huiliang Liu Flameless medical electronic atomizer
US11224704B2 (en) 2007-07-06 2022-01-18 Manta Devices, Llc Dose delivery device for inhalation
US8607787B2 (en) * 2007-07-06 2013-12-17 Manta Devices, Llc Dose delivery device for inhalation
US9713684B2 (en) 2007-07-06 2017-07-25 Manta Devices, Llc Dose delivery device for inhalation with plunger
US9919115B2 (en) 2007-07-06 2018-03-20 Manta Devices, Llc Dose delivery device for inhalation with first and second portions to open a dose chamber
US20160058958A1 (en) * 2009-07-17 2016-03-03 Nektar Therapeutics Systems and methods for driving sealed nebulizers
US11011270B2 (en) 2010-07-15 2021-05-18 Eyenovia, Inc. Drop generating device
US9087145B2 (en) 2010-07-15 2015-07-21 Eyenovia, Inc. Ophthalmic drug delivery
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
US10073949B2 (en) 2010-07-15 2018-09-11 Eyenovia, Inc. Ophthalmic drug delivery
US8684980B2 (en) 2010-07-15 2014-04-01 Corinthian Ophthalmic, Inc. Drop generating device
US8733935B2 (en) 2010-07-15 2014-05-27 Corinthian Ophthalmic, Inc. Method and system for performing remote treatment and monitoring
US11839487B2 (en) 2010-07-15 2023-12-12 Eyenovia, Inc. Ophthalmic drug delivery
US11398306B2 (en) 2010-07-15 2022-07-26 Eyenovia, Inc. Ophthalmic drug delivery
US10839960B2 (en) 2010-07-15 2020-11-17 Eyenovia, Inc. Ophthalmic drug delivery
US10646373B2 (en) 2011-12-12 2020-05-12 Eyenovia, Inc. Ejector mechanism, ejector device, and methods of use
US10639194B2 (en) 2011-12-12 2020-05-05 Eyenovia, Inc. High modulus polymeric ejector mechanism, ejector device, and methods of use
DE102014118578A1 (en) 2014-01-17 2015-07-23 Health & Life Co., Ltd. METHOD AND SPILL MODULE FOR A CONSTANT ELECTRICAL PERFORMANCE THROUGH AUTOMATIC COMPENSATION
US9713681B2 (en) 2014-01-17 2017-07-25 Health & Life Co., Ltd. Method and nebulization module providing constant electric power by automatic compensation
US11147936B2 (en) 2014-05-02 2021-10-19 Manta Devices, Llc Dose delivery device with cover connected to dose chamber seal
CN104826201A (en) * 2015-04-03 2015-08-12 齐俊民 Pediatric medical emergency atomizer
WO2017013072A1 (en) * 2015-07-22 2017-01-26 Linde Aktiengesellschaft A nebuliser
CN105288802A (en) * 2015-10-30 2016-02-03 李道恒 Ultrasonic atomization inhaler
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
US20200324225A1 (en) * 2017-05-04 2020-10-15 Flodesign Sonics, Inc. Acoustic transducer controller configuration
US11938056B2 (en) 2017-06-10 2024-03-26 Eyenovia, Inc. Methods and devices for handling a fluid and delivering the fluid to the eye
WO2019140788A1 (en) * 2018-01-18 2019-07-25 华健 Surge portable micro-network atomizer
US11583640B2 (en) 2018-04-20 2023-02-21 Gough Industries, Inc. Medicine vaporizer apparatus and methods of using the same
US11589610B2 (en) 2019-12-15 2023-02-28 Shaheen Innovations Holding Limited Nicotine delivery device having a mist generator device and a driver device
US11730899B2 (en) 2019-12-15 2023-08-22 Shaheen Innovations Holding Limited Mist inhaler devices
US11602165B2 (en) 2019-12-15 2023-03-14 Shaheen Innovations Holding Limited Nicotine delivery device having a mist generator device and a driver device
US11660406B2 (en) 2019-12-15 2023-05-30 Shaheen Innovations Holding Limited Mist inhaler devices
US11944121B2 (en) 2019-12-15 2024-04-02 Shaheen Innovations Holding Limited Ultrasonic mist inhaler with capillary element
US11666713B2 (en) 2019-12-15 2023-06-06 Shaheen Innovations Holding Limited Mist inhaler devices
EP4101317A1 (en) * 2019-12-15 2022-12-14 Shaheen Innovations Holding Limited Mist inhaler devices
US11672928B2 (en) 2019-12-15 2023-06-13 Shaheen Innovations Holding Limited Mist inhaler devices
US11700882B2 (en) 2019-12-15 2023-07-18 Shaheen Innovations Holding Limited Hookah device
US11717623B2 (en) 2019-12-15 2023-08-08 Shaheen Innovations Holding Limited Mist inhaler devices
US11724047B2 (en) 2019-12-15 2023-08-15 Shaheen Innovations Holding Limited Mist inhaler devices
US11730193B2 (en) 2019-12-15 2023-08-22 Shaheen Innovations Holding Limited Hookah device
US11730191B2 (en) 2019-12-15 2023-08-22 Shaheen Innovations Holding Limited Hookah device
US11571022B2 (en) 2019-12-15 2023-02-07 Shaheen Innovations Holding Limited Nicotine delivery device
US11744963B2 (en) 2019-12-15 2023-09-05 Shaheen Innovations Holding Limited Mist inhaler devices
US11785985B2 (en) 2019-12-15 2023-10-17 Shaheen Innovations Holding Limited Hookah device
US11819607B2 (en) 2019-12-15 2023-11-21 Shaheen Innovations Holding Limited Mist inhaler devices
US11819054B2 (en) 2019-12-15 2023-11-21 Shaheen Innovations Holding Limited Nicotine delivery device with airflow arrangement
US11944120B2 (en) 2019-12-15 2024-04-02 Shaheen Innovations Holding Limited Ultrasonic mist inhaler with capillary retainer
US11832646B2 (en) 2019-12-15 2023-12-05 Shaheen Innovations Holding Limited Nicotine delivery device with identification arrangement
EP3837999B1 (en) * 2019-12-15 2022-07-27 Shaheen Innovations Holding Limited Mist inhaler devices
US11878112B2 (en) 2019-12-15 2024-01-23 Shaheen Innovations Holding Limited Mist inhaler devices
US11911559B2 (en) 2019-12-15 2024-02-27 Shaheen Innovations Holding Limited Ultrasonic mist inhaler
US20210330621A1 (en) 2020-04-17 2021-10-28 United Therapeutics Corporation Treatment for interstitial lung disease
US11826327B2 (en) 2020-04-17 2023-11-28 United Therapeutics Corporation Treatment for interstitial lung disease
US11665483B1 (en) 2021-12-15 2023-05-30 Shaheen Innovations Holding Limited Apparatus for transmitting ultrasonic waves

Similar Documents

Publication Publication Date Title
US20030192532A1 (en) Nebulizer
CA2441190C (en) Methods and apparatus for controlling piezoelectric vibration
US4319155A (en) Nebulization control system for a piezoelectric ultrasonic nebulizer
US5487378A (en) Inhaler
EP0432992B1 (en) Dispensing apparatus
US8875697B2 (en) Drug delivery apparatus and method
KR100404720B1 (en) Sprayer
WO2019052506A1 (en) Ultrasonic electronic cigarette atomizer
JPH11504567A (en) Nebulizer
EP1092446A2 (en) Nebuliser
EP2744541B1 (en) A nebulizer, a control unit for controlling the same and a method of operating a nebulizer
US9038625B2 (en) Liquid spray device
JPH11128783A (en) Method for controlling electrostatic powder coating device and electrostatic powder coating device
KR102418190B1 (en) Ultrasonic nebulization device
CN116600842A (en) Detecting the presence of liquid in a vibrating membrane nebulizer
JP2565028Y2 (en) Mist generator
US11730896B2 (en) Multistage vaporizer for medical treatment system
JPH11123356A (en) Sprayer
WO2022242733A1 (en) Electronic atomization apparatus and control method
WO2000015282A1 (en) Nebulizer
CN117717196A (en) Electronic atomizing device and control method thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION